• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

≥60 岁成年人接种第三剂 SARS-CoV-2 BNT162b2 疫苗前后的抗体滴度。

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years.

机构信息

Rabin Medical Center, Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel.

Department of Oncology, Sheba Medical Center, Tel Hashomer, Israel.

出版信息

JAMA. 2021 Dec 7;326(21):2203-2204. doi: 10.1001/jama.2021.19885.

DOI:10.1001/jama.2021.19885
PMID:34739043
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8652594/
Abstract

This study assesses antispike (anti-S) IgG antibody titers before and after a third BNT162b2 dose (booster) in individuals aged 60 years and older in Israel.

摘要

本研究评估了以色列 60 岁及以上人群在接种第三剂 BNT162b2 （加强针）前后针对刺突蛋白（anti-S）的 IgG 抗体滴度。

相似文献

1
Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years.≥60 岁成年人接种第三剂 SARS-CoV-2 BNT162b2 疫苗前后的抗体滴度。
JAMA. 2021 Dec 7;326(21):2203-2204. doi: 10.1001/jama.2021.19885.
2
Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.SARS-CoV-2 感染受试者对 BNT162b2 mRNA COVID-19 疫苗的抗体反应。
Viruses. 2021 Mar 5;13(3):422. doi: 10.3390/v13030422.
3
Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.有或无前新冠病毒感染启动的情况下，SARS-CoV-2疫苗BNT162b2的抗体依赖性中和能力
J Intern Med. 2021 Dec;290(6):1272-1274. doi: 10.1111/joim.13366. Epub 2021 Aug 2.
4
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.评估接受癌症治疗的患者接种 BNT162b2 信使 RNA 疫苗后针对 SARS-CoV-2 的血清阳性率。
JAMA Oncol. 2021 Aug 1;7(8):1133-1140. doi: 10.1001/jamaoncol.2021.2155.
5
Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience.60 岁以上成年人接种 BNT162b2 信使 RNA 新冠肺炎疫苗第三剂的早期免疫原性和安全性：真实世界经验。
J Infect Dis. 2022 Mar 2;225(5):785-792. doi: 10.1093/infdis/jiab584.
6
Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers.疫苗类型和既往 SARS-CoV-2 感染与医护人员接种疫苗后症状和抗体测量的关联。
JAMA Intern Med. 2021 Dec 1;181(12):1660-1662. doi: 10.1001/jamainternmed.2021.4580.
7
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.辉瑞 BNT162b2 mRNA 新冠疫苗接种后体液免疫反应的综合评估：三例病例系列。
Clin Chem Lab Med. 2021 Apr 12;59(9):1585-1591. doi: 10.1515/cclm-2021-0339. Print 2021 Aug 26.
8
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.既往感染过严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的个体对第一剂BNT162b2的抗体反应。
Lancet. 2021 Mar 20;397(10279):1057-1058. doi: 10.1016/S0140-6736(21)00501-8. Epub 2021 Feb 25.
9
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.成年人实体瘤中接受两剂和三剂 BNT162b2 mRNA 疫苗的免疫反应。
Nat Med. 2021 Nov;27(11):2002-2011. doi: 10.1038/s41591-021-01542-z. Epub 2021 Sep 30.
10
Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.BNT162b2 mRNA新冠疫苗接种后糖尿病和非糖尿病个体均产生强劲抗体水平。
Front Immunol. 2021 Nov 24;12:752233. doi: 10.3389/fimmu.2021.752233. eCollection 2021.

引用本文的文献

1
Immune Durability and Breakthrough Infections 15 Months After SARS-CoV-2 Boosters in People over 65: The IMMERSION Study.65岁以上人群接种新冠病毒加强针15个月后的免疫持久性和突破性感染：IMMERSION研究
Vaccines (Basel). 2025 Jul 9;13(7):738. doi: 10.3390/vaccines13070738.
2
Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients.破解癌症患者预防新冠病毒突破性感染相关因素的密码。
Sci Rep. 2025 Mar 6;15(1):7858. doi: 10.1038/s41598-025-92254-8.
3
Reflections on COVID-19: A Literature Review of SARS-CoV-2 Testing.关于新冠疫情的思考：严重急性呼吸综合征冠状病毒2检测的文献综述
Vaccines (Basel). 2024 Dec 26;13(1):9. doi: 10.3390/vaccines13010009.
4
Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study.美国接种疫苗成年人中与SARS-CoV-2刺突1抗体反应相关的人口统计学和临床因素：C4R研究
Nat Commun. 2024 Feb 19;15(1):1492. doi: 10.1038/s41467-024-45468-9.
5
Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination.新冠病毒加强疫苗接种后抗SARS-CoV-2 IgA和IgG反应的动态变化及其对致命疾病的保护作用
Vaccines (Basel). 2023 Dec 21;12(1):12. doi: 10.3390/vaccines12010012.
6
Humoral and Cellular Immune Responses of People Living With Human Immunodeficiency Virus After 3 Doses of Messenger RNA BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine: A Prospective Cohort Study.3剂信使核糖核酸BNT162b2严重急性呼吸综合征冠状病毒2疫苗接种后人类免疫缺陷病毒感染者的体液免疫和细胞免疫反应：一项前瞻性队列研究
Open Forum Infect Dis. 2023 Jul 10;10(8):ofad347. doi: 10.1093/ofid/ofad347. eCollection 2023 Aug.
7
Longitudinal study of humoral immunity against SARS-CoV-2 of health professionals in Brazil: the impact of booster dose and reinfection on antibody dynamics.巴西卫生专业人员针对 SARS-CoV-2 的体液免疫的纵向研究：加强针和再感染对抗体动态的影响。
Front Immunol. 2023 Jul 14;14:1220600. doi: 10.3389/fimmu.2023.1220600. eCollection 2023.
8
Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases.炎症性肠病患者接种第三剂 COVID-19 BNT162b2 疫苗后的血清学反应及安全性
Vaccines (Basel). 2023 Jul 20;11(7):1263. doi: 10.3390/vaccines11071263.
9
Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population.医护人员加强接种 mRNA 疫苗后 6 个月内 SARS-CoV-2 变异体抗体分析及中和活性比较。
Front Immunol. 2023 May 17;14:1166261. doi: 10.3389/fimmu.2023.1166261. eCollection 2023.
10
Immune Response to SARS-CoV-2 Vaccination in Cancer Patients: A Prospective Study.癌症患者对SARS-CoV-2疫苗接种的免疫反应：一项前瞻性研究。
Cureus. 2023 Apr 1;15(4):e37014. doi: 10.7759/cureus.37014. eCollection 2023 Apr.

本文引用的文献

1
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.辉瑞-BioNTech 新冠疫苗接种 6 个月后免疫体液反应逐渐减弱。
N Engl J Med. 2021 Dec 9;385(24):e84. doi: 10.1056/NEJMoa2114583. Epub 2021 Oct 6.
2
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.辉瑞-BioNTech 疫苗加强针在以色列预防新冠病毒。
N Engl J Med. 2021 Oct 7;385(15):1393-1400. doi: 10.1056/NEJMoa2114255. Epub 2021 Sep 15.
3
Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses.肾移植受者对两剂mRNA-1273 SARS-CoV-2疫苗血清学反应微弱，接种第三剂后的抗体反应
JAMA. 2021 Jul 23;326(11):1063-5. doi: 10.1001/jama.2021.12339.
4
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection.新型冠状病毒血清阳性抗体检测与未来感染风险的关系。
JAMA Intern Med. 2021 May 1;181(5):672-679. doi: 10.1001/jamainternmed.2021.0366.
5
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.两种基于 RNA 的新冠候选疫苗的安全性和免疫原性。
N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14.
6
COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses.COVID-19 疫苗 BNT162b1 可引发人体抗体和 T1 T 细胞应答。
Nature. 2020 Oct;586(7830):594-599. doi: 10.1038/s41586-020-2814-7. Epub 2020 Sep 30.